Unknown OBSERVATIONAL NCT03758248

The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI

Sponsor: Beijing Anzhen Hospital

Conditions Antiplatelet Therapy CYP2C19 Polymorphism

Interventions CYP2C19

Updated 8 times since 2018 Last updated: Dec 4, 2020 Started: Dec 1, 2018 Primary completion: Aug 31, 2021 Completion: Sep 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Antiplatelet Therapy and CYP2C19 Polymorphism, this trial is ongoing. The trial is conducted by Beijing Anzhen Hospital and has accumulated 8 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Dec 2021 — Feb 2023 [monthly]

Recruiting
Jan 2021 — Dec 2021 [monthly]

Recruiting

▶ Show 3 earlier versions

Nov 2020 — Jan 2021 [monthly]

Recruiting
Jun 2019 — Nov 2020 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Dec 2018 — Jun 2019 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Anzhen Hospital

Data source: Beijing Anzhen Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China